CHICAGO -- Electronic nudges increased uptake of flu vaccines among patients with a history of acute myocardial infarction ...

We are also eligible to receive up to $700 million in additional milestone payments related to our COVID-19 vaccine and ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite ...

Sanofi 'surprised' by PAI Partners' raised bid for Opella unit October 17, 2024 The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu ...

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...

We are also eligible to receive up to $700 million in additional milestone payments related to our COVID-19 vaccine and Sanofi's own combination COVID-flu vaccine. Along with future milestone ...

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13.Don't Miss our ...

Note: Due to a pricing disagreement with the French government, Sanofi’s HD flu vaccine Efluelda, intended for people older than 65 years, will not be available this year. (See: Withdrawal of ...

(Bloomberg) -- Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached €2.86 ($ ...